AFT Pharmaceuticals (NZSE:AFT) Moat Score: 0/10 (As of Jul. 03, 2026)


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.67
GF Value NZ$4.16
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Moat Score?

AFT Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

AFT Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AFT Pharmaceuticals might have No Moat - No discernible moat.

AFT Pharmaceuticals  (NZSE:AFT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AFT Pharmaceuticals Moat Score Related Terms

NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.67 is trading 11.8% below its estimated GF Value™ of NZ$4.16. GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NZSE:AFT:

  • Moat Score: 0
  • GF Value™: NZ$4.16 vs. price of NZ$3.67 (11.8% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.67
Price
NZ$4.16
GF Value